You are viewing: India Sepsis Diagnostics Market analysis
Part of: Sepsis Diagnostics Market (Global)

The India Sepsis Diagnostics Market was valued at $23.6 Million in 2024 and projected to reach to $36.2 Million by 2029, representing a compound annual growth rate of 8.9%. India's sepsis diagnostics market is positioned for substantial growth as healthcare providers increasingly recognize sepsis as a critical clinical priority.

India Sepsis Diagnostics Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Sepsis Diagnostics Market Trends and Insights

  • This expansion reflects India's increasing healthcare infrastructure investments and rising awareness of sepsis as a critical clinical challenge.
  • India's market growth rate of 8.9% CAGR outpaces global trends, driven by higher disease burden, growing hospital admissions, and improving diagnostic accessibility across urban and semi-urban centers. The sepsis diagnostics landscape in India is characterized by rising adoption of rapid diagnostic technologies and point-of-care testing solutions.
  • India's healthcare sector is increasingly prioritizing early sepsis detection to reduce mortality rates, particularly in intensive care units and emergency departments.
  • Between 2024 and 2029, India is expected to see significant investments in diagnostic infrastructure, supported by government healthcare initiatives and private sector expansion. India's market dynamics are shaped by cost-sensitive healthcare delivery models and the need for affordable yet accurate diagnostic solutions.
  • The country's large patient population and high prevalence of infectious diseases create substantial demand for sepsis diagnostics in India, positioning the market as a key growth region within Asia Pacific..

Key Market Statistics

  • CAGR (2024-2029) 8.9% CAGR
  • Market Size, 2024 ~USD 23.6 Million
  • Forecast, 2029 ~USD 36.2 Million
  • Country India

India Sepsis Diagnostics Market Overview

Rapid Market Expansion :

India's sepsis diagnostics market is growing at 8.9% CAGR, significantly outpacing the global growth rate of 7%, driven by increasing healthcare investments and rising sepsis awareness across Indian hospitals and diagnostic centers.

High Disease Burden :

India faces a substantial sepsis disease burden due to high infection rates, limited early diagnostic capabilities, and growing patient populations in both urban and rural healthcare settings, creating urgent demand for advanced diagnostic solutions.

Healthcare Infrastructure Development :

Expanding hospital networks, government healthcare initiatives, and increasing adoption of point-of-care testing technologies in India are accelerating the deployment of sepsis diagnostic tools across tier-1, tier-2, and emerging tier-3 cities.

Market Valuation Growth :

The Indian sepsis diagnostics market is valued at $23.6 million in 2024 and is projected to reach $36.2 million by 2029, representing a 53% increase over the five-year forecast period with sustained momentum.

India Sepsis Diagnostics Market Dynamics

  • The country's expanding hospital infrastructure, coupled with government initiatives to improve diagnostic capabilities, creates a favorable environment for market expansion.
  • Rising awareness among clinicians and patients about early sepsis detection is driving adoption of advanced diagnostic technologies across major metropolitan areas and secondary care centers. The market's 8.9% CAGR reflects India's unique combination of high disease prevalence, growing healthcare spending, and improving access to diagnostic services.
  • Key drivers include increasing ICU capacity, rising prevalence of infectious diseases, and growing demand for rapid, accurate diagnostic solutions.
  • As India continues to strengthen its healthcare ecosystem and invest in diagnostic infrastructure, the sepsis diagnostics market is expected to attract significant investment from both domestic and international players..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Key Takeaways

    • India's sepsis diagnostics market is valued at $23.6 million in 2024 and will reach $36.6 million by 2029, growing at 8.9% CAGR.
    • India's market growth rate exceeds global averages, driven by high disease burden and expanding healthcare infrastructure.
    • Cost-effective diagnostic solutions and point-of-care testing are critical success factors in India's price-sensitive healthcare market.
    • Government healthcare initiatives and private sector investments are accelerating sepsis diagnostic adoption across India's hospital network.

    Sepsis Diagnostics Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment POINT-OF-CARE TESTS (Test Type)
    Forecast Period 2024–2029
    Growth Rate CAGR of 7% from 2024 to 2029
    Largest Segment BLOOD CULTURE (Technology)
    Market Size Base Year (Billions) ~USD 0.63 (2024)
    Revenue Forecast (Billions) ~USD 0.89 (2029)
    Segments Covered Technology, Product, Method, Pathogen Type, Type, Test Type, End User

    India Sepsis Diagnostics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Technology

    • Biomarkers
    • Blood Culture
    • Flow Cytometry
    • Immunoassays
    • Microfluidics
    • Molecular Diagnostics

    By Product

    • Assays & Reagent Kits
    • Blood Culture Media
    • Instruments
    • Software

    By Method

    • Automated Diagnostics
    • Conventional Diagnostics

    By Pathogen Type

    • Bacterial Sepsis
    • Fungal Sepsis
    • Other Pathogen Types

    By Type

    • Dna Sequencing
    • Gram-Negative Bacteria
    • Gram-Negative Bacterial Sepsis
    • Gram-Positive Bacteria
    • Gram-Positive Bacterial Sepsis
    • Microarrays
    • Peptide Nucleic Acid-Fluorescent In Situ Hybridization
    • Polymerase Chain Reaction

    By Test Type

    • Laboratory Tests
    • Point-Of-Care Tests

    By End User

    • Hospitals And Specialty Clinics
    • Pathology And Reference Laboratories
    • Research Laboratories, Academic Institutes, And Cros

    Target Audience

    • Diagnostic Device Manufacturers : Manufacturers need India-specific market intelligence to develop localized product strategies, understand regulatory requirements, identify distribution partners, and capitalize on the 8.9% CAGR growth opportunity.
    • Healthcare Investors & PE Firms : Investment firms require detailed India market data to evaluate portfolio opportunities, assess market attractiveness, identify acquisition targets, and make informed capital allocation decisions in the Indian healthcare sector.
    • Hospital & Diagnostic Center Operators : Healthcare providers need market insights to benchmark their sepsis diagnostic capabilities, understand competitive positioning, identify technology partnerships, and optimize service offerings for Indian patient populations.
    • Government & Healthcare Policy Bodies : Policy makers and government agencies require market analysis to inform healthcare infrastructure planning, diagnostic standards development, and resource allocation for sepsis management across Indian healthcare systems.
    • Pharmaceutical & Biotech Companies : Companies developing sepsis-related therapeutics need market data to understand diagnostic adoption rates, identify clinical trial opportunities, and align product development with India's sepsis management landscape.

    Key Companies in the India Sepsis Diagnostics Market

    CompanyHQOwnershipStrongest segments
    CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler system and associated reagents,Collaborative and specialized assays (e.g., TB, Ebola, USPS BDS),
    NANOSPHERE, INCUnited StatesPrivate CompanyInfectious disease molecular assays,Pharmacogenetic and human genetic assays,Protein and ultra-sensitive multiplex assays,
    TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, VCM, EDC, sodium bicarbonate),Polymers and petrochemicals (PE, EVA, PVC pastes, synthetic rubber, functional polymers),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia),
    BIOMÉRIEUXFrancePublic CompanyClinical microbiology (ID/AST, blood culture, culture media),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EMAG),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
    BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (syringes, needles, vascular access, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related tools),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables),
    T2 BIOSYSTEMS, INC.United StatesPublic CompanyT2Dx instrument,T2Candida panel,T2Bacteria panel,
    DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious & Gastrointestinal Diseases, Hepatitis & Retroviruses,Immunodiagnostics – Endocrinology & Metabolic Disorders,Tumor Markers and Oncology Assays,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    BRUKER CORPORATIONUnited StatesPublic CompanyBSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and molecular diagnostics),BSI Nano (X-ray, AFM, electron microscopy tools),
    QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
    SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
    ABBOTT LABORATORIESUnited StatesPublic CompanyMedical Devices,Diagnostic Products,Nutritional Products,
    SIEMENS HEALTHINEERSGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
    QIAGEN N.V.NetherlandsPublic CompanySample technology consumables (nucleic acid stabilization/purification),Immune response and infectious disease assays (incl. TB IGRA),Oncology and sexual/reproductive health assays,
    SEEGENE, INC.South KoreaPublic CompanyRespiratory disease detection,Gastrointestinal disease detection,STI and HPV detection,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Healthcare Solutions (EMR, receipt, pharmacy, wellness),Diagnostic and Life Sciences Equipment,

    CEPHEID INC.

    Cepheid Inc. is a private molecular diagnostics company founded in 1996 in the United States with 1,700 employees. The company develops and manufactures diagnostic systems and tests.

    NANOSPHERE, INC

    Nanosphere, Inc. is a private diagnostic company founded in 1998 in the United States with 148 employees. The company focuses on molecular diagnostic technologies.

    TOSOH CORPORATION

    Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees. The company operates across multiple business segments including diagnostics and healthcare products.

    BIOMÉRIEUX

    bioMérieux is a French public company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases and industrial microbiology.

    BECTON, DICKINSON AND COMPANY

    Becton, Dickinson and Company is a United States public company founded in 1897 with 72,000 employees. The company is a global medical technology manufacturer producing diagnostic systems, devices, and reagents.

    DANAHER CORPORATION

    Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses including diagnostics and life sciences.

    T2 BIOSYSTEMS, INC.

    T2 Biosystems, Inc. is a United States public company founded in 2006 with 113 employees. The company develops rapid diagnostic technologies for infectious diseases.

    DIASORIN S.P.A.

    DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company manufactures and distributes in vitro diagnostic products.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and diagnostic solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical systems for research and diagnostics.

    QUIDELORTHO CORPORATION

    Qiagen N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.

    SYSMEX CORPORATION

    QuidelOrtho Corporation is a United States public company founded in 1979 with 6,500 employees. The company develops and manufactures rapid diagnostic tests and point-of-care solutions.

    ABBOTT LABORATORIES

    Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and reagents.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company develops and manufactures diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.

    QIAGEN N.V.

    QIAGEN N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.

    SEEGENE, INC.

    Seegene, Inc. is a South Korean public company founded in 2000 with 216 employees. The company develops and manufactures molecular diagnostic products and multiplex PCR technologies.

    PHC HOLDINGS CORPORATION

    PHC Holdings Corporation is a Japanese public company founded in 1948 with 8,647 employees. The company manufactures and sells medical devices and diagnostic equipment.

    Reasons to Buy this Report

    • India-Specific Market Sizing : Obtain precise valuation data for India's sepsis diagnostics market with detailed 2024-2029 forecasts, enabling accurate business planning and investment decisions tailored to the Indian healthcare landscape.
    • Competitive Landscape Analysis : Understand the competitive dynamics specific to India, including local and international players, market share distribution, and strategic positioning within the rapidly growing Indian diagnostic sector.
    • Growth Driver Identification : Identify India-specific growth catalysts including healthcare infrastructure investments, government initiatives, disease prevalence patterns, and adoption trends that differentiate India from global markets.
    • Regional Expansion Strategy : Develop targeted market entry and expansion strategies for India by understanding tier-wise market opportunities, regional healthcare variations, and distribution channel preferences across different Indian markets.
    • Investment & Partnership Opportunities : Identify high-potential investment, partnership, and acquisition opportunities within India's sepsis diagnostics ecosystem, including emerging players, technology providers, and healthcare institutions.

    Frequently asked questions

    What is the current size of India's sepsis diagnostics market?

    India's sepsis diagnostics market was valued at $23.6 million in 2024 and is projected to grow to $36.2 million by 2029.

    What is the growth rate of India's sepsis diagnostics market?

    India's sepsis diagnostics market is growing at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2029.

    What factors are driving growth in India's sepsis diagnostics market?

    Key drivers include rising healthcare infrastructure investments, high disease burden, growing hospital admissions, government healthcare initiatives, and increasing adoption of rapid diagnostic technologies in India.

    Which diagnostic technologies are most relevant to India's sepsis market?

    Point-of-care testing, rapid diagnostic assays, and cost-effective blood culture systems are particularly relevant to India's price-sensitive healthcare environment and expanding diagnostic infrastructure.

    How does India's sepsis diagnostics market compare to global trends?

    India's market growth rate of 8.9% CAGR exceeds the global average of 7%, reflecting higher disease prevalence and accelerating healthcare modernization across the country.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the sepsis diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the sepsis diagnostics market. The primary sources from the demand side include OEMs, private and contract testing organizations and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Sepsis Diagnostics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation Methodology

    In this report, the global sepsis diagnostics market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the sepsis diagnostics products business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Approach 1: Procedure-based estimation approach

    To calculate the global market value, installation/volume consumption of sepsis diagnostic products were calculated. This process involved the following steps:

    • Finding the total number of hospitalization at the regional and/or country-level
    • The average number of sepsis cases at the regional and/or country level
    • The average number of sepsis diagnostics tests performed per patient at the regional and/or country-level
    • The average selling price of each product type for a given year was triangulated to arrive at the market value data at the regional and/or country-level

    Sepsis Diagnostics Market Size Estimation

    Approach 2: End user-based market estimation

    During preliminary secondary research, the total sales revenue of sepsis diagnostics was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

    • Generating a list of major customer facilities across each region and country
    • Identifying the average number of sepsis diagnostics product supplies used by major customer facilities across each product type at the regional/country level, annually
    • Identifying the percentage contribution of major customer facilities to the overall sepsis diagnostics expenditure and usage at the regional/country level, annually
    • Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually

    Sepsis Diagnostics Market Size Estimation

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global sepsis diagnostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the sepsis diagnostics market was validated using both top-down and bottom-up approaches.

    Market Definition

    Sepsis is a life-threatening condition caused by pathogen infection. It develops when chemicals released into the bloodstream to fight the infection trigger inflammatory responses throughout the body. This is a three-stage syndrome—from sepsis to severe sepsis and septic shock. Septic shock is the last stage that results in extremely low blood pressure and a lack of response to normal fluid replacement. Inflammation leads to multi-organ failure; progress to septic shock could lead to death.

    Key Market Stakeholders

    • Sepsis diagnostics reagents, instruments, blood culture media manufacturers
    • Research & academic laboratories
    • Healthcare service providers (including hospitals, reference labs, diagnostic centers, and specialty clinics)
    • Market research and consulting firms
    • Medical device suppliers, distributors, channel partners, and third-party suppliers
    • Business research and consulting service providers
    • Venture capitalists and other government funding organizations

    Objectives of the Study

    • To define, describe, and forecast the sepsis diagnostics market on the basis of on technology, product, method, pathogen type, test type, end user and region.
    • To provide detailed information regarding the major factors influencing the growth potential of the global sepsis diagnostics market (drivers, restraints, opportunities, challenges, and trends).
    • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global sepsis diagnostics market.
    • To analyze key growth opportunities in the global sepsis diagnostics market for key stakeholders and provide details of the competitive landscape for market leaders.
    • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa (GCC Countries and Rest of MEA).
    • To profile the key players in the global sepsis diagnostics market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global sepsis diagnostics market, such as agreements, expansions, and & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global sepsis diagnostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to 15)

    Geographic Analysis

    • Further breakdown of the Rest of Europe's sepsis diagnostics market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
    • Further breakdown of the Rest of Asia Pacific sepsis diagnostics market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
    • Further breakdown of the Rest of the Latin America sepsis diagnostics market into Argentina, Chile, Peru, and Colombia, among other

    Get the Full Sepsis Diagnostics Market Report

    Full forecast, segment splits, and company analysis for all Sepsis Diagnostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status